Vaccines
US biopharmaceuticals company Merck has dropped plans for a £1 billion investment in a major new London life sciences lab, citing the UK's failure to make meaningful progress in addressing the lack of investment in the life science industry and the undervaluation of innovative medicines and vaccines by
Biological products industry
KKR & Co. Inc. has strengthened its presence in the biopharma industry by acquiring a majority ownership stake in HealthCare Royalty Partners (HCRx), a leading biopharma royalty acquisition company. Founded in 2006, HCRx has a strong track record of investing in commercial-stage and near-commercial-stage biopharmaceutical assets, with a portfolio spanning
AIDS treatment
MSF welcomes the release of new World Health Organization (WHO) HIV prevention guidelines recommending wider use of lenacapavir, an injectable version of pre-exposure prophylaxis (PrEP) that only needs to be administered two times per year. The organization is urging Gilead Sciences, the developer of lenacapavir, to make it more accessible
Biological products industry
Gilead Sciences Inc has showcased the efficacy and tolerability of twice-yearly injectable lenacapavir (Yeztugo) for HIV pre-exposure prophylaxis (PrEP) across diverse populations, including pregnant and lactating women, adolescents, and young adults. The new data from the Phase 3 PURPOSE trials highlighted zero HIV infections among pregnant and breastfeeding participants on
Biological products industry
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, has announced a significant breakthrough in its CAR-T therapy development, NXC-201. The therapy has showcased a class-leading safety profile, including the absence of neurotoxicity of any grade in low-volume disease to-date. This achievement paves the way for potential future indication expansion, solidifying the
Biological products industry
The Food and Drug Administration has approved a new, twice-a-year injectable HIV prevention medication, lenacapavir, which has been shown to be highly effective in preventing new infections. The medication, which will be marketed as Yeztugo, offers a more convenient alternative to existing daily HIV prevention pills, which have adherence rates
Securities law
Sutro Biopharma, Inc. has filed a Form 8-K report with the U.S. Securities and Exchange Commission following its 2025 Annual Meeting of Stockholders, where key proposals regarding the election of directors, the appointment of an independent registered public accounting firm, and the approval of executive compensation and a reverse
Securities law
Investors who purchased or acquired stock of Zenas BioPharma, Inc. (NASDAQ: ZBIO) in connection with the company's initial public offering (IPO) on September 13, 2024, may be eligible to join a securities class action lawsuit. The lawsuit, filed in federal court, alleges that the company and its executives
Securities law
Theravance Biopharma, Inc. has filed a current report with the US Securities and Exchange Commission, announcing the settlement of ongoing patent litigation with Eugia Pharma Specialities Ltd. over the YUPELRI(R) (revefenacin) inhalation solution. Under the terms of the agreement, Theravance granted Eugia a non-exclusive license to manufacture and market
Biological products industry
Aspire Biopharma Holdings, a developer of a patent-pending drug delivery technology, is set to present at the Sidoti Virtual Investor Conference on May 21. The company's CEO, Kraig Higginson, will lead the presentation, which will be accessible via the virtual conference platform. Additionally, Aspire Biopharma will host virtual
Biological products industry
Lenacapavir, a first-in-class HIV capsid inhibitor, is currently under development by Gilead Sciences for human immunodeficiency virus (HIV) prevention as pre-exposure prophylaxis (PrEP). According to Gilead Sciences, clinical trial results demonstrate the potential of lenacapavir in ending new HIV infections worldwide. The company is committed to working with various stakeholders
Biological products industry
Enzo Biochem, a life sciences company operating for over 45 years, has announced that its Board of Directors has commenced a review of strategic alternatives. This move follows recent inquiries regarding a potential transaction with the Company. An independent special committee, the Strategic Committee, has been formed to evaluate various
